ROUTE-C3G: A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain (clinicaltrials.gov) - Sep 30, 2026 - P=N/A | N=35 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis
|